Parkinson’s is the fastest growing neurological condition in the world and affects around 153,000 people in the UK.

Shares of GSK PLC GSK inched down 0.55% to £15.28 Monday, on what proved to be an all-around favorable trading session for ...

New Mechanistic Insights Underscore Multiple Potential Roles for Elraglusib as an Immune Modulator in the treatment of NeuroblastomaStudy ...

Discover Vicebio's molecular clamp technology as it completes a $100 million series B round for its bivalent vaccine against ...

There hasn’t been a new class of drugs approved to help smokers quit since Pfizer's Chantix reached the market nearly two ...

The former head of vaccine R&D at GSK has pulled together $100 million for a London-based biotech working on respiratory ...

comments a Future Market Insights analyst. Zydus Healthcare Ltd., Sun Pharmaceutical Industries Ltd., Sanofi SA, GSK Plc, ...

Peripheral blood mononuclear cells (PBMCs) collected from 10 patients with active AS patients were exposed to TP, GSK-J4 or vehicle. T lymphocyte subsets were analyzed using flow cytometry. ELISA was ...

The GSK share price has had a rotten few years and now it's heading south yet again. Investor Harvey Jones continues to hang ...

GSK PLC GSK shares slipped 2.45% to £15.36 Friday, on what proved to be an all-around grim trading session for the stock ...

Bank of America Securities analyst Graham Parry maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) yesterday and set a ...